MedTrace Logo

Buprenorphine for Treatment Resistant Depression

NCT01407575 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-03-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the safety and efficacy of buprenorphine with placebo for adults with treatment resistant depression (TRD).

Conditions

  • Depression
  • Depressive Disorder
  • Depressive Disorder, Major

Interventions

DRUG

Buprenorphine

low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)

DRUG

Placebo

matched placebo

Sponsors & Collaborators

  • National Alliance for Research on Schizophrenia and Depression

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Jordan F Karp, M.D. · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01407575 on ClinicalTrials.gov